Antibody Persistence Following Administration of a Hexavalent DTwP-IPV-HB-PRP~T Vaccine Versus Separate DTwP-HB-PRP~T and IPV Vaccines and Safety and Immunogenicity of a Booster Dose of DTwP-IPV-HB-PRP~T Administered With an MMR Vaccine in Healthy Infants in India.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
medline:
16
11
2023
pubmed:
18
10
2023
entrez:
18
10
2023
Statut:
ppublish
Résumé
Antibody persistence of a whole-cell pertussis-containing hexavalent vaccine (DTwP-IPV-HB-PRP~T) and its co- or sequential administration with measles, mumps, rubella (MMR) vaccine were evaluated. Phase III, open-label, randomized, multicenter study in India. Healthy toddlers 12-24 months of age who had received DTwP-IPV-HB-PRP~T or separate DTwP-HB-PRP~T+IPV primary vaccination at 6-8, 10-12 and 14-16 weeks of age received a DTwP-IPV-HB-PRP~T booster concomitantly with MMR (N = 336) or 28 days before MMR (N = 340). Participants had received a first dose of measles vaccine. Immunogenicity assessment used validated assays and safety was by parental reports. All analyses were descriptive. All participants had prebooster anti-T ≥0.01 IU/mL and anti-polio 1 and 3 ≥8 1/dil, and ≥96.5% had anti-D ≥0.01 IU/mL, anti-HBs ≥10 mIU/mL, anti-polio 2 ≥8 1/dil and anti-PRP ≥0.15 µg/mL; for pertussis, antibody persistence was similar in each group. Postbooster immunogenicity for DTwP-IPV-HB-PRP~T was similar for each antigen in each group: ≥99.5% of participants had anti-D ≥0.01 IU/mL, anti-T ≥0.01 IU/mL, anti-polio 1, 2 and 3 >8 1/dil, anti-HBs ≥10 mIU/mL and anti-PRP ≥1 µg/mL; for pertussis, vaccine response was similar in each group [72.0%-75.9% (anti-PT), 80.8%-81.4% (anti-FIM), 77.6%-79.5% (anti-PRN), 78.2%-80.8% (anti-FHA)]. There was no difference in MMR immunogenicity between groups, and no difference in DTwP-IPV-HB-PRP~T booster immunogenicity based on the primary series. There were no safety concerns. DTwP-IPV-HB-PRP~T antibody persistence was similar to licensed comparators. Booster immunogenicity was robust after DTwP-IPV-HB-PRP~T with or without MMR, and MMR immunogenicity was not affected by coadministration with DTwP-IPV-HB-PRP~T. CTRI/2020/04/024843.
Sections du résumé
BACKGROUND
BACKGROUND
Antibody persistence of a whole-cell pertussis-containing hexavalent vaccine (DTwP-IPV-HB-PRP~T) and its co- or sequential administration with measles, mumps, rubella (MMR) vaccine were evaluated.
METHODS
METHODS
Phase III, open-label, randomized, multicenter study in India. Healthy toddlers 12-24 months of age who had received DTwP-IPV-HB-PRP~T or separate DTwP-HB-PRP~T+IPV primary vaccination at 6-8, 10-12 and 14-16 weeks of age received a DTwP-IPV-HB-PRP~T booster concomitantly with MMR (N = 336) or 28 days before MMR (N = 340). Participants had received a first dose of measles vaccine. Immunogenicity assessment used validated assays and safety was by parental reports. All analyses were descriptive.
RESULTS
RESULTS
All participants had prebooster anti-T ≥0.01 IU/mL and anti-polio 1 and 3 ≥8 1/dil, and ≥96.5% had anti-D ≥0.01 IU/mL, anti-HBs ≥10 mIU/mL, anti-polio 2 ≥8 1/dil and anti-PRP ≥0.15 µg/mL; for pertussis, antibody persistence was similar in each group. Postbooster immunogenicity for DTwP-IPV-HB-PRP~T was similar for each antigen in each group: ≥99.5% of participants had anti-D ≥0.01 IU/mL, anti-T ≥0.01 IU/mL, anti-polio 1, 2 and 3 >8 1/dil, anti-HBs ≥10 mIU/mL and anti-PRP ≥1 µg/mL; for pertussis, vaccine response was similar in each group [72.0%-75.9% (anti-PT), 80.8%-81.4% (anti-FIM), 77.6%-79.5% (anti-PRN), 78.2%-80.8% (anti-FHA)]. There was no difference in MMR immunogenicity between groups, and no difference in DTwP-IPV-HB-PRP~T booster immunogenicity based on the primary series. There were no safety concerns.
CONCLUSIONS
CONCLUSIONS
DTwP-IPV-HB-PRP~T antibody persistence was similar to licensed comparators. Booster immunogenicity was robust after DTwP-IPV-HB-PRP~T with or without MMR, and MMR immunogenicity was not affected by coadministration with DTwP-IPV-HB-PRP~T.
CLINICAL TRIALS REGISTRY INDIA NUMBER
UNASSIGNED
CTRI/2020/04/024843.
Identifiants
pubmed: 37851978
doi: 10.1097/INF.0000000000004118
pii: 00006454-202312000-00030
doi:
Substances chimiques
Vaccines, Combined
0
Measles-Mumps-Rubella Vaccine
0
Poliovirus Vaccine, Inactivated
0
Antibodies, Bacterial
0
Diphtheria-Tetanus-Pertussis Vaccine
0
Hepatitis B Antibodies
0
Haemophilus Vaccines
0
Hepatitis B Vaccines
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1128-1135Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Decker M, Edwards K, Bogaerts H. Combination vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, eds. Vaccines. 7th ed. PA, USA: Elsevier; 2018. 198–227.
Indian Academy of Pediatrics. IAP immunization timetable 2014: IAP recommended vaccines for routine use. Available at: https://immunizeindia.org/files/immschedule.pdf . Accessed May 9, 2023.
Mangarule S, Palkar S, Mitra M, et al. Safety and immunogenicity of a hexavalent DTwP-IPV-HB-PRP~T vaccine versus separate DTwP-HB-PRP~T and IPV vaccines in healthy infants in India. Vaccine X. 2022;10:100137.
Mangarule S, Palkar S, Mitra M, et al. Antibody persistence following administration of a hexavalent DTwP-IPV-HB-PRP~T vaccine versus separate DTwP-HB-PRP~T and IPV vaccines at 12-24 months of age and safety and immunogenicity of a booster dose of DTwP-IPV-HB-PRP~T in healthy infants in India. Vaccine X. 2022;11:100190.
Mangarule S, Prasanth S, Kawade A, et al. Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP~T vaccine and non-inferiority to separate DTwP-HB-PRP~T and IPV antigen-matching vaccines at 6-8, 10-12, and 14-16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: a multi-center, randomized, controlled study. Vaccine X. 2022;12:100216.
WHO. WHO Prequalified Vaccines. Available at: https://extranet.who.int/gavi/PQ_Web/ . Accessed May 9, 2023.
Singh N, Madkaikar NJ, Gokhale PM, et al. New drugs and clinical trials rules 2019: Changes in responsibilities of the ethics committee. Perspect Clin Res. 2020;11:37–43.
Itell HL, McGuire EP, Muresan P, et al. Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines. Vaccine. 2018;36:5600–5608.
Varghese K, Bartlett W, Zheng L, et al. A new electrochemiluminescence-based multiplex assay for the assessment of human antibody responses to bordetella pertussis vaccines. Infect Dis Ther. 2021;10:2539–2561.
Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med. 1998;17:873–890.
WHO. WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19. 11 March 2020. Available at: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 . Accessed May 9, 2023.